Loading...

Brilliant Violet 510™ anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_BV510_CD4_Antibody_FC_082312
Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
  • OKT4_BV510_CD4_Antibody_FC_082312
    Human peripheral lymphocytes were stained with CD3 APC and CD4 (clone OKT4) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Save
317443 25 tests ¥38,720
317444 100 tests ¥86,020
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Carre C, et al. 2021. iScience. 24:102970. PubMed
  2. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  3. Ghassemi S, et al. 2022. Nat Biomed Eng. 6:118. PubMed
  4. Asashima H, et al. 2022. J Clin Invest. 132: . PubMed
  5. Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed
  6. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  7. Boucher LE, et al. 2023. MAbs. 15:2195517. PubMed
  8. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  9. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  10. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  11. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
  12. Kasper M, et al. 2021. Elife. 10:. PubMed
  13. Vijayakumar B, et al. 2022. Immunity. . PubMed
  14. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  15. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  16. Guedan S, et al. 2018. JCI Insight. 3. PubMed
  17. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  18. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  19. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
  20. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
  21. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  22. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  23. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  24. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
  25. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
  26. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  27. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
  28. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
  29. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  30. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
  31. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  32. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
  33. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  34. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
  35. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
  36. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  37. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  38. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  39. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
  40. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
  41. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
  42. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  43. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
RRID
AB_2561866 (BioLegend Cat. No. 317443)
AB_2561866 (BioLegend Cat. No. 317444)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account